AIM ImmunoTech Inc.(AIM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AIM AIM ImmunoTech Inc.

盘后交易 07-06 19:18:42 EDT

0.2970

+0.0170

+6.07%

盘后0.2899

-0.0071-2.39%

19:18 EDT

最高0.2984	最低0.2850	成交量63.07万
今开0.2892	昨收0.2800	日振幅4.79%
总市值823.41万	流通市值741.58万	总股本2,772万
成交额18.46万	换手率2.53%	流通股本2,497万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AIM","market":"US","secType":"STK","nameCN":"AIM ImmunoTech Inc.","latestPrice":0.297,"timestamp":1783368000000,"preClose":0.28,"halted":0,"volume":630718,"hourTrading":{"tag":"盘后","latestPrice":0.2899,"preClose":0.297,"latestTime":"19:18 EDT","volume":22261,"amount":6539.424751500001,"timestamp":1783379886201,"change":-0.0071,"changeRate":-0.023906,"amplitude":0.02862},"delay":0,"changeRate":0.06071428571428556,"floatShares":24969100,"shares":27724200,"eps":-7.3888,"marketStatus":"盘后交易","change":0.017,"latestTime":"07-06 19:18:42 EDT","open":0.2892,"high":0.2984,"low":0.285,"amount":184587.48775346,"amplitude":0.047857,"askPrice":0.3065,"askSize":170,"bidPrice":0.2648,"bidSize":107,"shortable":3,"etf":0,"ttmEps":-7.3888,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783382400000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":0.28,"preHourTrading":{"tag":"盘前","latestPrice":0.2874,"preClose":0.2865,"latestTime":"09:29 EDT","volume":79011,"amount":23535.461673359998,"timestamp":1783344599999,"change":0.0009,"changeRate":0.003141,"amplitude":0.090052},"postHourTrading":{"tag":"盘后","latestPrice":0.2899,"preClose":0.297,"latestTime":"19:18 EDT","volume":22261,"amount":6539.424751500001,"timestamp":1783379886201,"change":-0.0071,"changeRate":-0.023906,"amplitude":0.02862},"volumeRatio":0.439519},"requestUrl":"/m/hq/s/AIM/","defaultTab":"news","newsList":[{"id":"2646538352","title":"雷神技术公司获价值11亿美元美国海军AIM-9X第二批次导弹合同。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646538352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646538352?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:01","pubTimestamp":1782475279,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0640476718.USD","AIM","LU0683600562.USD","IE00B775SV38.USD","LU1162221912.USD","LU0787776722.HKD","LU1430594728.SGD","LU1280957306.USD","BK4187","RTX","BK4550","LU1585245621.USD","BK4557","BK4139","BK4588","LU1366192091.USD","IE00B3S45H60.SGD","RTXG","LU1929549753.HKD","BK4566","LU0320765646.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155685980","title":"AIM ImmunoTech 加速推进潜在关键性胰腺癌项目，Ampligen 持续跨越关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1155685980","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155685980?lang=zh_cn&edition=full","pubTime":"2026-06-24 20:29","pubTimestamp":1782304165,"startTime":"0","endTime":"0","summary":"随着其核心药物 Ampligen 在临床试验中不断取得关键进展，AIM ImmunoTech 正全速推进其潜在的、决定性的胰腺癌治疗项目。这一进展标志着公司在开发针对这一难治性癌症的免疫疗法道路上迈出了重要一步。\nAmpligen 的持续进步为整个研发管线注入了强劲动力。公司正集中资源，旨在加速该胰腺癌项目向更具决定性的临床阶段迈进。每一步的跨越都使 AIM 更接近为患者提供新的治疗选择这一目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126055655","title":"AIM ImmunoTech提交文件，拟由售股股东发售及转售至多1308万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1126055655","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126055655?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:09","pubTimestamp":1781788194,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 已向美国证券交易委员会提交相关文件。根据该文件，公司计划由售股股东进行一项股票发售与转售行动，涉及股份数量最高可达1308万股普通股。此举旨在为现有股东提供流动性选项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4139","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149038141","title":"AIM ImmunoTech向SEC提交文件，计划由售股股东发售及转售至多1308万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149038141","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149038141?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:05","pubTimestamp":1781784305,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech公司已向美国证券交易委员会提交相关文件。根据该文件，公司的现有股东计划面向市场，发售及转售高达1308万股普通股。此举意味着部分持股人正寻求减持其股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4139","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115821813","title":"AIM ImmunoTech：根据SEC文件，售股股东拟发售及再售最多3130万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115821813","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115821813?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:09","pubTimestamp":1780949356,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件披露，AIM ImmunoTech Inc.的售股股东计划发售及再售公司普通股，总量最高可达3130万股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","AIM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111192858","title":"AIM ImmunoTech公布中期积极临床进展：Ampligen®联合阿斯利康Imfinzi®治疗胰腺癌的二期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111192858","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111192858?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:33","pubTimestamp":1780921999,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech公司公布了其针对胰腺癌治疗的二期临床研究的中期积极进展。该研究旨在评估其药物Ampligen与阿斯利康的Imfinzi联合疗法的效果。此次公布的中期数据展现了令人鼓舞的临床发展态势。研究探索了这种联合用药方案在治疗胰腺癌患者中的潜力。胰腺癌作为一种侵袭性强、治疗选择有限的恶性肿瘤，新的有效疗法备受期待。后续的完整临床数据将为进一步评估该联合疗法的安全性与有效性提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177685141","title":"AIM ImmunoTech提前完成Duripanc二期试验患者入组关键节点，推动Ampligen迈向胰腺癌关键临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177685141","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177685141?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:59","pubTimestamp":1780318759,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech公司宣布，其针对胰腺癌的Duripanc二期临床试验已提前完成患者入组目标。这一进展标志着公司核心候选药物Ampligen在攻克这一难治性癌症的临床开发道路上，迈出了至关重要的一步。该里程碑的达成，为后续评估Ampligen联合标准疗法治疗胰腺导管腺癌的有效性与安全性铺平了道路，加速了其向关键临床节点推进的进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4557","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192345437","title":"AIM ImmunoTech宣布240万美元融资，包括同步进行的注册直接发行与私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1192345437","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192345437?lang=zh_cn&edition=full","pubTime":"2026-05-21 03:04","pubTimestamp":1779303853,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech公司近日公布了一项总额达240万美元的融资计划。该融资方案结合了同步进行的注册直接发行与私募配售。这一举措旨在为公司提供额外的运营资金，支持其研发与业务拓展活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130658270","title":"AIM ImmunoTech Inc. 将本票到期日延长至2027年6月30日；未偿余额为168万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130658270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130658270?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:07","pubTimestamp":1779192448,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 宣布，已将其一项本票的到期期限延长。新的到期日设定为2027年6月30日。根据公司披露的信息，该票据当前的未偿还本金余额为168万美元。此举为公司管理其债务结构提供了更长的缓冲时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136334748","title":"AIM ImmunoTech宣布股东权益显著增长及本票到期日延至2027年6月，提升财务灵活性并支持战略临床重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1136334748","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136334748?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:02","pubTimestamp":1779192142,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 近日宣布了两项关键的财务进展，旨在强化其资产负债表并为未来的战略推进提供动力。公司股东权益实现了显著提升，同时，一项重要的本票到期日已成功延长至2027年6月。这些举措共同增强了公司的财务灵活性，使其能够更专注于推进核心的临床研发优先事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4557","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111519376","title":"AIM ImmunoTech就晚期胰腺癌疗法Ampligen拟定三期临床试验规划签署协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1111519376","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111519376?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:01","pubTimestamp":1772460104,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 已签署一项协议，旨在规划其核心候选药物Ampligen用于治疗晚期胰腺癌的一项拟议三期临床试验。此举标志着该公司在推进该免疫疗法针对这一难治癌症的临床开发进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIM","BK4557","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147759942","title":"AIM ImmunoTech宣布将先前公布的配股认购期延长至2026年3月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=1147759942","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147759942?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:07","pubTimestamp":1772028423,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 近日发布公告，决定将其先前已宣布的配股计划中的股东认购权利行使期限进行延长。新的最终截止日期现已确定为2026年3月3日。此举为公司股东提供了更为充裕的时间来考虑并行使其在此次融资活动中的相关权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4139","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142732216","title":"AIM ImmunoTech公布Ampligen与阿斯利康Durvalumab联合治疗转移性胰腺癌的二期试验规划里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1142732216","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142732216?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:58","pubTimestamp":1771855089,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 近日披露了其正在进行的二期临床试验的关键规划节点，该试验旨在评估其核心药物Ampligen与阿斯利康（AstraZeneca）的Durvalumab联合用于治疗转移性胰腺癌的疗效。公司明确了试验推进过程中的若干重要阶段，标志着该联合疗法研发进程的稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIM","BK4557","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110033028","title":"AIM ImmunoTech公布Ampligen®联合阿斯利康Imfinzi®治疗胰腺癌的II期研究年终中期积极临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1110033028","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110033028?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:45","pubTimestamp":1770299127,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 宣布，其评估Ampligen®联合阿斯利康Imfinzi®用于治疗胰腺癌的II期研究，在年终时取得了积极的中期临床进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIM","BK4139","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607645065","title":"Aim Immunotech Inc.盘中异动 股价大跌5.74%报1.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607645065","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607645065?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:57","pubTimestamp":1769713071,"startTime":"0","endTime":"0","summary":"北京时间2026年01月30日02时57分，Aim Immunotech Inc.股票出现波动，股价大幅跳水5.74%。截至发稿，该股报1.15美元/股，成交量6.1535万股，换手率1.92%，振幅4.92%。Aim Immunotech Inc.股票所在的生物技术行业中，整体跌幅为0.42%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc 是一家免疫制药公司，专注于研究和开发用于治疗多种癌症、病毒性疾病和免疫缺陷疾病的疗法，以及治疗目前疗法不足或未得到满足的癌症。Ampligen 已获准在阿根廷共和国进行商业销售，用于治疗严重的慢性疲劳综合症 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130025751953efc34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130025751953efc34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","AIM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603568688","title":"Aim Immunotech Inc.盘中异动 快速下挫6.20%报1.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603568688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603568688?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:39","pubTimestamp":1768228770,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时39分，Aim Immunotech Inc.股票出现波动，股价急速下跌6.20%。截至发稿，该股报1.21美元/股，成交量1.6471万股，换手率0.56%，振幅4.66%。Aim Immunotech Inc.股票所在的生物技术行业中，整体跌幅为1.24%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc 是一家免疫制药公司，专注于研究和开发用于治疗多种癌症、病毒性疾病和免疫缺陷疾病的疗法，以及治疗目前疗法不足或未得到满足的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222393197a1768a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222393197a1768a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4139","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518522411","title":"Aim Immunotech Inc.盘中异动 快速拉升5.26%报0.140美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518522411","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518522411?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613723,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Aim Immunotech Inc.股票出现波动，股价大幅上涨5.26%。截至发稿，该股报0.140美元/股，成交量6.2388万股，换手率0.09%，振幅7.52%。Aim Immunotech Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc是一家免疫制药公司，致力于研究和开发治疗免疫失调、病毒和癌症疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213523a26a262e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213523a26a262e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517944046","title":"Aim Immunotech Inc.盘中异动 急速上涨5.27%报0.130美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517944046?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:59","pubTimestamp":1741193960,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时59分，Aim Immunotech Inc.股票出现波动，股价快速上涨5.27%。截至发稿，该股报0.130美元/股，成交量33.1625万股，换手率0.48%，振幅9.97%。Aim Immunotech Inc.股票所在的生物技术行业中，整体涨幅为1.08%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc是一家免疫制药公司，致力于研究和开发治疗免疫失调、病毒和癌症疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306005920989d674b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306005920989d674b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4139","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516608703","title":"Aim Immunotech Inc.盘中异动 早盘大幅下挫5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516608703?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:14","pubTimestamp":1741101264,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时14分，Aim Immunotech Inc.股票出现异动，股价急速跳水5.91%。截至发稿，该股报0.113美元/股，成交量26.1457万股，换手率0.38%，振幅10.07%。Aim Immunotech Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc是一家免疫制药公司，致力于研究和开发治疗免疫失调、病毒和癌症疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231424abe7fc8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231424abe7fc8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AIM","BK4139","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634735","title":"Aim Immunotech Inc.盘中异动 股价大跌5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634735?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012370,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Aim Immunotech Inc.股票出现异动，股价急速跳水5.63%。截至发稿，该股报0.127美元/股，成交量11.5122万股，换手率0.17%，振幅6.67%。Aim Immunotech Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Aim Immunotech Inc.公司简介：AIM ImmunoTech Inc是一家免疫制药公司，致力于研究和开发治疗免疫失调、病毒和癌症疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223250abe633a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223250abe633a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AIM","BK4139","BK4557"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aimimmuno.com","stockEarnings":[{"period":"1week","weight":-0.2122},{"period":"1month","weight":-0.6613},{"period":"3month","weight":-0.5294},{"period":"6month","weight":-0.7645},{"period":"1year","weight":-0.9694},{"period":"ytd","weight":-0.752}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AIM ImmunoTech Inc.成立于1966年，是一家总部位于佛罗里达州奥卡拉的免疫制药集团，专注于研发针对癌症、病毒性疾病和免疫缺陷疾病的疗法，尤其针对那些现有治疗选择有限的疾病。公司已积累了大量关于核酸和天然干扰素疗法的实验室、临床前和临床数据，旨在增强人体的抗病毒防御能力，并支持某些癌症和慢性疾病的治疗研发。AIM的产品组合包括Ampligen（rintatolimod），一种正在开发用于治疗肿瘤、病毒和免疫系统疾病的双链RNA分子；以及Alferon N注射液（干扰素α）。Ampligen尚未获得美国食品药品监督管理局（FDA）的批准，但已在阿根廷获准上市销售，用于治疗重度慢性疲劳综合征。","yearOnYearQuotes":[{"month":1,"riseRate":0.551724,"avgChangeRate":0.167884},{"month":2,"riseRate":0.344828,"avgChangeRate":0.019452},{"month":3,"riseRate":0.517241,"avgChangeRate":0.035765},{"month":4,"riseRate":0.448276,"avgChangeRate":0.020276},{"month":5,"riseRate":0.357143,"avgChangeRate":0.032622},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.001427},{"month":7,"riseRate":0.321429,"avgChangeRate":-0.024032},{"month":8,"riseRate":0.310345,"avgChangeRate":0.010354},{"month":9,"riseRate":0.37931,"avgChangeRate":-0.054048},{"month":10,"riseRate":0.37931,"avgChangeRate":0.04782},{"month":11,"riseRate":0.206897,"avgChangeRate":-0.091583},{"month":12,"riseRate":0.344828,"avgChangeRate":-0.100787}],"exchange":"AMEX","name":"AIM ImmunoTech Inc.","nameEN":"AIM ImmunoTech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AIM ImmunoTech Inc.(AIM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AIM ImmunoTech Inc.(AIM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AIM ImmunoTech Inc.,AIM,AIM ImmunoTech Inc.股票,AIM ImmunoTech Inc.股票老虎,AIM ImmunoTech Inc.股票老虎国际,AIM ImmunoTech Inc.行情,AIM ImmunoTech Inc.股票行情,AIM ImmunoTech Inc.股价,AIM ImmunoTech Inc.股市,AIM ImmunoTech Inc.股票价格,AIM ImmunoTech Inc.股票交易,AIM ImmunoTech Inc.股票购买,AIM ImmunoTech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AIM ImmunoTech Inc.(AIM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AIM ImmunoTech Inc.(AIM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}